Comparison of Single-Dose of Albuterol Breath Activated Inhaler Versus Albuterol Metered Dose Inhaler in Asthmatics
Completed
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 4
2007-01-01
This is a research study designed to compare the single-dose effectiveness of
albuterol-HFA-BAI (breath activated inhaler) and albuterol-HFA-MDI (metered dose inhaler) in
asthmatics with poor inhaler coordinating abilities. Patients must be 7 to 70 years of age to
participate in this study.
Comparison of Single-Dose of Albuterol Breath Activated Inhaler Versus Albuterol Metered Dose Inhaler in Asthmatics
Completed
Teva Branded Pharmaceutical Products, R&D Inc.
Phase 4
2007-01-01
This is a research study designed to compare the single-dose effectiveness of
albuterol-HFA-BAI (breath activated inhaler) and albuterol-HFA-MDI (metered dose inhaler) in
asthmatics with poor inhaler coordinating abilities. Patients must be 7 to 70 years of age to
participate in this study.
Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.
Completed
AstraZeneca
Phase 3
2007-09-01
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED
patients with refractory acute asthma helps improve forced expiratory volume at one second
(FEV1) and decrease the need for hospitalization.
Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.
Completed
Jacobi Medical Center
Phase 3
2007-09-01
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED
patients with refractory acute asthma helps improve forced expiratory volume at one second
(FEV1) and decrease the need for hospitalization.
Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.
Completed
Nassau University Medical Center
Phase 3
2007-09-01
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED
patients with refractory acute asthma helps improve forced expiratory volume at one second
(FEV1) and decrease the need for hospitalization.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
